AMGN Stock Down Despite Q3 Earnings & Sales Beat, Raised Guidance
Amgen (AMGN) reported Q3 2026 earnings of $6.45 per share, beating estimates. Revenue rose 8% to $10.37B, also surpassing expectations. Key drugs like Repatha and Evenity saw strong growth, while Prolia and Xgeva declined due to biosimilar competition. Amgen raised its full-year guidance, but shares fell 2% after-hours.
How this was made
The 30-second read
Why it matters
The earnings beat and guidance raise provide fresh data for valuation models; the after‑hours dip suggests short‑term downside pressure.
Market read
Primary earnings release for a large‑cap biotech; new numbers and guidance are material for traders.
What to watch
Strong growth in rare‑disease and oncology lines could offset biosimilar erosion in the longer term.
Background
Amgen's Q3 results include double‑digit growth in several products and a guidance raise, but stock fell due to weakness in legacy drugs.
Ticker impact
Amgen reported Q3 2026 earnings beat and raised full-year revenue and earnings guidance.
likely modest pressure as market digests guidance that is only slightly above expectations despite beat.
The earnings release is the first report of the numbers and guidance, providing new data for traders; the after‑hours price dip suggests short‑term downside risk.
Market effects
Biotech sector may see mixed reaction as Amgen's guidance aligns with expectations while product mix shifts.
U.S. large‑cap biotech index could see slight pullback.
Limited; primarily impacts Amgen and peers.
Counterpoint
Despite the beat, the guidance raise may be viewed as insufficient, supporting a short bias.
Key entities
- companyAmgen Inc.
US‑listed biotech firm reporting Q3 earnings.
